Niagen Bioscience, Inc. (NAGE) research
Niagen Bioscience, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $2.99
- As of
Niagen Bioscience, Inc. (NAGE): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-04.
As of . Source: SEC EDGAR filings for NAGE. Method and limitations.
Share the NAGE intelligence card
See NAGE live in the terminal
Track NAGE's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live NAGE terminal, freeActive signals for NAGE
- highCONSENSUS_SELL
4 tracked funds reduced NAGE this 2026Q2, institutional consensus
- highCONSENSUS_SELL
4 tracked funds reduced NAGE this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 50% of NAGE (2026Q2)
- highINSTITUTIONAL_EXIT
RENAISSANCE TECHNOLOGIES LLC cut 50% of NAGE (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 75% of NAGE (2026Q2)
FREE, NO ACCOUNT
Every signal on NAGE, as it fires
You are seeing 5 of 29 signals recorded on NAGE since 2026-06-05.
The five above landed across 2 days. The other 24 were recorded on 2 other days. 21 of the 29 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in NAGE (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 171077407 · 2026Q2 | $2.1M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 171077407 · 2026Q2 | $2M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 171077407 · 2026Q2 | $879K | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 171077407 · 2026Q2 | $319K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, NAGE
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
NAGE mentioned in Kresmion daily briefs
NAGE against its peers
NAGE's operating margin of 12.6% ranks in the 82nd percentile of 13 Biotechnology sub-industry peers, fiscal periods ending between 2025-09-30 and 2025-12-31.
| Metric | NAGE | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 129M USD | 25.4M USD | 82 | 13 |
| Gross margin | 64.3% | n/a | n/a | 2 |
| Operating margin | 12.6% | -251.6% | 82 | 13 |
| Net margin | 13.4% | -229.6% | 82 | 13 |
| Return on equity | 22.7% | -47.0% | 86 | 17 |
| P / E | 14.9x | n/a | n/a | 1 |
Peers (18): ALXO, CGEN, SLGL, ADAG, YDES, WHWK, IVVD, KROS, NGEN, BCYC, AVXL, MGNX, ANTX, TRDA, NKTX, PLX, LCTX, ACIU. Left out: TNXP (no annual filing), VRXA (no annual filing). Fiscal periods ending between 2025-09-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (NAGE: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more NAGE signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to NAGEand get the insider, 13F, options, and confluence read in one view.